Aberrant methylation of TRIM58 in hepatocellular carcinoma and its potential clinical implication

Oncology Reports

Volumn 36, Issue 2, 2016, Pages 811-818

  Qiu, Xueping ^a   Huang, Yifang ^a   Zhou, Ye ^a   Zheng, Fang ^a  

^a ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

DNA methylation; Hepatocellular carcinoma; mRNA expression; TRIM58

Indexed keywords

MESSENGER RNA; TRIPARTITE MOTIF PROTEIN; UBIQUITIN PROTEIN LIGASE;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DNA METHYLATION; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENE FUNCTION; HUMAN; HUMAN TISSUE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; ONCOGENE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SURVIVAL RATE; TRIPARTITE MOTIF CONTAINING 58 GENE; CPG ISLAND; GENE EXPRESSION REGULATION; GENETICS; LIVER TUMOR; MIDDLE AGED; PATHOLOGY; PROGNOSIS;

CARCINOMA, HEPATOCELLULAR; CPG ISLANDS; DISEASE-FREE SURVIVAL; DNA METHYLATION; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; RNA, MESSENGER; TRIPARTITE MOTIF PROTEINS; UBIQUITIN-PROTEIN LIGASES;

EID: 84976504334     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2016.4871     Document Type: Article

References (30)

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin 65: 87-108, 2015.
2. El-Serag HB: Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 142: 1264-1273.e1, 2012.
3. Forner A, Llovet JM and Bruix J: Hepatocellular carcinoma. Lancet 379: 1245-1255, 2012.
4. Shibata T and Aburatani H: Exploration of liver cancer genomes. Nat Rev Gastroenterol Hepatol 11: 340-349, 2014.
5. Pogribny IP and Rusyn I: Role of epigenetic aberrations in the development and progression of human hepatocellular carcinoma. Cancer Lett 342: 223-230, 2014.
6. You JS and Jones PA: Cancer genetics and epigenetics: Two sides of the same coin? Cancer Cell 22: 9-20, 2012.
7. Um TH, Kim H, Oh BK, Kim MS, Kim KS, Jung G and Park YN: Aberrant CpG island hypermethylation in dysplastic nodules and early HCC of hepatitis B virus-related human multistep hepatocarcinogenesis. J Hepatol 54: 939-947, 2011.
8. Raggi C and Invernizzi P: Methylation and liver cancer. Clin Res Hepatol Gastroenterol 37: 564-571, 2013.
9. Mikeska T, Bock C, Do H and Dobrovic A: DNA methylation biomarkers in cancer: Progress towards clinical implementation. Expert Rev Mol Diagn 12: 473-487, 2012.
10. Sceusi EL, Loose DS and Wray CJ: Clinical implications of DNA methylation in hepatocellular carcinoma. HPB Oxf 13: 369-376, 2011.
11. Napolitano LM and Meroni G: TRIM family: Pleiotropy and diversification through homomultimer and heteromultimer formation. IUBMB Life 64: 64-71, 2012.
12. Thom CS, Traxler EA, Khandros E, Nickas JM, Zhou OY, Lazarus JE, Silva AP, Prabhu D, Yao Y, Aribeana C, et al: Trim58 degrades Dynein and regulates terminal erythropoiesis. Dev Cell 30: 688-700, 2014.
13. Tao R, Li J, Xin J, Wu J, Guo J, Zhang L, Jiang L, Zhang W, Yang Z and Li L: Methylation profile of single hepatocytes derived from hepatitis B virus-related hepatocellular carcinoma. PLoS One 6: e19862, 2011.
14. Qiu X, Hu B, Huang Y, Deng Y, Wang X and Zheng F: Hypermethylation of ACP1, BMP4, and TSPYL5 in hepatocellular carcinoma and their potential clinical significance. Dig Dis Sci 61: 149-157, 2016.
15. Zhang X, Liu S, Shen C, Wu Y, Zhang L, Chen X and Lu F: DNA methylation consistency implicates the primary tumor cell origin of recurrent hepatocellular carcinoma. Epigenomics 7: 581-592, 2015.
16. Wang Y, Cheng J, Xu C, Liu S, Jiang S, Xu Q, Chen X, Zhuang H and Lu F: Quantitative methylation analysis reveals gender and age differences in p16INK4a hypermethylation in hepatitis B virus-related hepatocellular carcinoma. Liver Int 32: 420-428, 2012.
17. Zhang X, Wang J, Cheng J, Ding S, Li M, Sun S, Zhang L, Liu S, Chen X, Zhuang H, et al: An integrated analysis of SOCS1 downregulation in HBV infection-related hepatocellular carcinoma. J Viral Hepat 21: 264-271, 2014.
18. Gao XD, Qu JH, Chang XJ, Lu YY, Bai WL, Wang H, Xu ZX, An LJ, Wang CP, Zeng Z, et al: Hypomethylation of long interspersed nuclear element-1 promoter is associated with poor outcomes for curative resected hepatocellular carcinoma. Liver Int 34: 136-146, 2014.
19. Villanueva A, Portela A, Sayols S, Battiston C, Hoshida Y, Méndez-González J, Imbeaud S, Letouzé E, Hernandez-Gea V, Cornella H, et al; HEPTROMIC Consortium: DNA methylationbased prognosis and epidrivers in hepatocellular carcinoma. Hepatology 61: 1945-1956, 2015.
20. Mah WC, Thurnherr T, Chow PK, Chung AY, Ooi LL, Toh HC, Teh BT, Saunthararajah Y and Lee CG: Methylation profiles reveal distinct subgroup of hepatocellular carcinoma patients with poor prognosis. PLoS One 9: e104158, 2014.
21. Yan T, Zhao JJ, Bi XY, Zhao H, Huang Z, Li ZY, Zhou JG, Li Y, Li C, Cai JQ, et al: Prognosis of hepatocellular carcinoma: A study of 832 cases. Zhonghua Zhong Liu Za Zhi 35: 54-58, 2013 (In Chinese).
22. Tandon P and Garcia-Tsao G: Prognostic indicators in hepatocellular carcinoma: A systematic review of 72 studies. Liver Int 29: 502-510, 2009.
23. Lu W, Dong J, Huang Z, Guo D, Liu Y and Shi S: Comparison of four current staging systems for Chinese patients with hepatocellular carcinoma undergoing curative resection: Okuda, CLIP, TNM and CUPI. J Gastroenterol Hepatol 23: 1874-1878, 2008.
24. Fukushige S and Horii A: DNA methylation in cancer: A gene silencing mechanism and the clinical potential of its biomarkers. Tohoku J Exp Med 229: 173-185, 2013.
25. Gan L, Chen S, Zhong J, Wang X, Lam EK, Liu X, Zhang J, Zhou T, Yu J, Si J, et al: ZIC1 is downregulated through promoter hypermethylation, and functions as a tumor suppressor gene in colorectal cancer. PLoS One 6: e16916, 2011.
26. Zhong S, Tang MW, Yeo W, Liu C, Lo YM and Johnson PJ: Silencing of GSTP1 gene by CpG island DNA hypermethylation in HBV-associated hepatocellular carcinomas. Clin Cancer Res 8: 1087-1092, 2002.
27. Kaur P, Mani S, Cros MP, Scoazec JY, Chemin I, Hainaut P and Herceg Z: Epigenetic silencing of sFRP1 activates the canonical Wnt pathway and contributes to increased cell growth and proliferation in hepatocellular carcinoma. Tumour Biol 33: 325-336, 2012.
28. He G, Hu S, Zhang D, Wu P, Zhu X, Xin S, Lu G, Ding Y and Liang L: Hypermethylation of FOXD3 suppresses cell proliferation, invasion and metastasis in hepatocellular carcinoma. Exp Mol Pathol 99: 374-382, 2015.
29. Shin SH, Lee KH, Kim BH, Lee S, Lee HS, Jang JJ and Kang GH: Downregulation of spleen tyrosine kinase in hepatocellular carcinoma by promoter CpG island hypermethylation and its potential role in carcinogenesis. Lab Invest 94: 1396-1405, 2014.
30. Xu X, Liu RF, Wan BB, Xing WM, Huang J and Han ZG: Expression of a novel gene FAM43B repressing cell proliferation is regulated by DNA methylation in hepatocellular carcinoma cell lines. Mol Cell Biochem 354: 11-20, 2011.